Synapse - Works

Results (5225)

Ruxolitinib in combination with dasatinib and dexamethasone is an active and well-tolerated chemotherapy-sparing oral induction regimen for adults with Philadelphia chromosome-positive ALL: Results of a phase I trial

Meeting Abstract

Geyer, M. B.; Burke, P. W.; King, A. C.; Mauro, M. J.; Tallman, M. S.; Levine, R. L.; Sherr, C. J.; Douer, D.; Park, J. H.
Blood (2018)

Fulltext@MSK | Save

Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)

Meeting Abstract

Goldberg, A. D.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Menghrajani, K.; Patel, M.; Cai, S.; Dunbar, A.; Epstein-Peterson, Z. D.; McGovern, E.; more...
Blood (2018)

Fulltext@MSK | Save

Calibrated CAR activation potential directs alternative T cell fates and therapeutic potency

Meeting Abstract

Feucht, J.; Sun, J.; Eyquem, J.; Ho, Y. J.; Zhao, Z.; Leibold, J.; Dobrin, A.; Cabriolu, A.; Hamieh, M.; Sadelain, M.
Blood (2018)

Fulltext@MSK | Save

Therapeutic disassembly of leukemogenic enhancer complexes

Meeting Abstract

Forbes, L.; Isaac, K.; Dinares, G. M.; Kharas, M. G.; Kentsis, A.
Blood (2018)

Fulltext@MSK | Save

Minimal residual disease (MRD) at time of complete remission is commonly detected in acute myeloid leukemia (AML) patients age ≥ 60 years and significantly impacts outcome based on post-remission treatment strategies: Prospective analysis of ECOG-ACRIN (E-A) E2906 phase III trial

Meeting Abstract

Foran, J. M.; Sun, Z.; Paietta, E.; Racevskis, J.; Claxton, D. F.; Lazarus, H. M.; Arber, D. A.; Rowe, J. M.; Altman, J. K.; Al-Kali, A.; more...
Blood (2018)

Fulltext@MSK | Save

Prediction of CAR T-related toxicities in R/R DLBCL patients treated with axicabtagene ciloleucel using point of care cytokine measurements

Meeting Abstract

Faramand, R.; Kotani, H.; Morrissey, D.; Yu, B.; Locke, F. L.; Jain, M. D.; Chavez, J. C.; Wang, X.; Mishra, A.; Bachmeier, C. A.; more...
Blood (2018)

Fulltext@MSK | Save

Activating mutations in CSF1R and additional receptor tyrosine kinases in sporadic and familial histiocytic neoplasms

Meeting Abstract

Durham, B. H.; Lopez-Rodrigo, E.; Abramson, D. H.; Picarsic, J.; Pastore, A.; Mandelker, D.; Walsh, M. F.; Arcila, M. E.; Ladanyi, M.; Solit, D.; more...
Blood (2018)

Fulltext@MSK | Save

Expression of the butyrate/niacin receptor, GPR109a on T cells plays an important role in a mouse model of graft versus host disease

Meeting Abstract

Docampo, M. D.; Stein-Thoeringer, C. K.; Lazrak, A.; Burgos da Silva, M. D.; Cross, J.; van den Brink, M. R. M.
Blood (2018)

Fulltext@MSK | Save

Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome: Results from a phase 1 dose escalation and expansion study

Meeting Abstract

DiNardo, C. D.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Foran, J. M.; Stone, R. M.; Patel, P. A.; more...
Blood (2018)

Fulltext@MSK | Save

Small-molecule targeting of Musashi RNA-binding activity in acute myeloid leukemia

Meeting Abstract

Dinares, G. M.; Albanese, S. K.; Chow, A.; Schurer, A.; Park, S. M.; Rotsides, C. Z.; Taggart, J.; Rizzi, A.; Naden, L. N.; Chou, T.; more...
Blood (2018)

Fulltext@MSK | Save